Immunic (IMUX) Chief Medical Officer Michael Panzara files initial Form 3 insider report

Rhea-AI Filing Summary

IMMUNIC, INC. filed an initial Form 3 for Chief Medical Officer Michael A. Panzara, establishing his status as a reporting person for the company’s securities. The filing does not list any buy, sell, or derivative transactions and serves as a baseline disclosure of insider reporting obligations.

Key Figures

Net buy/sell shares: 0 shares Buy transactions: 0 Sell transactions: 0 +1 more

4 metrics

Net buy/sell shares 0 shares Form 3 transaction summary

Buy transactions 0 Form 3 transaction summary

Sell transactions 0 Form 3 transaction summary

Exercise transactions 0 Form 3 transaction summary

Key Terms

Form 3, beneficial ownership, Chief Medical Officer

3 terms

Form 3 regulatory

"filed an initial Form 3 for Chief Medical Officer Michael A. Panzara"

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

beneficial ownership regulatory

"serves as his initial beneficial ownership report"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

Chief Medical Officer financial

"identifies Michael A. Panzara as Chief Medical Officer and a reporting person"

A chief medical officer is a senior executive responsible for overseeing the health and medical strategies within an organization, often in the healthcare or pharmaceutical sectors. They play a key role in guiding decisions related to medical research, product safety, and healthcare policies, which can impact a company's reputation and success. For investors, understanding the chief medical officer's role helps gauge how well a company manages medical risks and advances its healthcare goals.

Understanding Insider Trading Forms →

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Panzara Michael A.

(Last) (First) (Middle)

1200 AVENUE OF THE AMERICAS, SUITE 200

(Street)

NEW YORK NEW YORK 10036

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
04/24/2026

3. Issuer Name and Ticker or Trading Symbol
IMMUNIC, INC. [ IMUX ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

No securities are beneficially owned.

No securities are beneficially owned.

	/s/ Grant Levine, attorney-in-fact	04/28/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does the IMMUNIC (IMUX) Form 3 filing for Michael A. Panzara show?

The Form 3 filing identifies Michael A. Panzara as Chief Medical Officer and a reporting person for IMMUNIC. It serves as his initial beneficial ownership report and shows no reported purchases, sales, or derivative transactions in IMMUNIC securities at this time.

Did IMMUNIC (IMUX) Chief Medical Officer Michael A. Panzara buy or sell shares in this Form 3?

This Form 3 does not report any purchases or sales of IMMUNIC shares by Michael A. Panzara. The transaction summary shows zero buy, sell, exercise, gift, tax-withholding, or restructuring transactions, indicating no trading activity is being disclosed in this filing.

What is the purpose of a Form 3 for IMMUNIC (IMUX) insiders?

Form 3 is an initial beneficial ownership statement for company insiders such as officers, directors, or large shareholders. It establishes their reporting status with the SEC so that any future trades in IMMUNIC securities can be disclosed through subsequent Forms 4 or 5.

Does the IMMUNIC (IMUX) Form 3 for Michael A. Panzara include derivative securities?

The Form 3 shows no derivative positions for Michael A. Panzara. The derivative summary is empty and the transaction summary lists zero derivative transactions, indicating no options, warrants, or similar derivative securities are reported in this particular filing excerpt.

What trading activity summary is disclosed for IMMUNIC (IMUX) in this Form 3?

The trading summary for this Form 3 reports zero buys, zero sells, zero exercises, and zero gifts, with net buy/sell shares listed as zero. This means the filing functions purely as an initial ownership report, without any contemporaneous trading activity being disclosed.